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Abstract
Background: In women with rheumatoid arthritis (RA) it has been observed that during pregnancy a majority of
patients experience amelioration, but after delivery a relapse of the disease is common. However, there are few
studies, with diverging results, addressing the effect of parity on the severity of RA over time. Our aim was to
explore the impact of parity, with stratification for anti-citrullinated protein antibody (ACPA) status as well as for
onset during reproductive age or not.
Methods: Female RA cases aged 18–70 years were recruited for the Epidemiological Investigation of Rheumatoid
Arthritis (EIRA). Information on disease severity (the health assessment questionnaire (HAQ) and the disease activity
score 28 (DAS28)) was retrieved from the Swedish Rheumatology Quality Register at inclusion and 3, 6, 12 and
24 months after diagnosis. Mixed models were used to compare mean DAS28 and HAQ scores over time in parous
and nulliparous women. Mean differences at individual follow-up visits were compared using analysis of covariance.
The odds of having DAS28 or HAQ above the median in parous verus nulliparous women were estimated in logistic
regression models.
Results: A total of 1237 female cases (mean age 51 years, 65 % ACPA-positive) were included. ACPA-negative parous
women, aged 18–44 years, had on average 1.17 units higher DAS28 (p < 0.001) and 0.43 units higher HAQ score
(p < 0.001) compared to nulliparous women during the follow-up time, adjusted for age. In this subgroup, the
average DAS28 and HAQ scores were significantly higher in parous women at all follow-up time points. Younger
parous ACPA-negative women were significantly more likely to have DAS28 and HAQ values above the median
compared to nulliparous women at all follow-up visits. No association between parity and severity of ACPA-positive
disease was observed.
Conclusions: Parity was a predictor of a more severe RA among ACPA-negative younger women, which might
indicate that immunomodulatory changes during and after pregnancy affect RA severity, in particular for the
ACPA-negative RA phenotype.
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Background
Female sex and older age are known risk factors for
rheumatoid arthritis (RA). The disease is, however, hetero-
geneous, and a common division occurs between the
presence/absence of autoantibodies to citrullinated peptide
antigens (ACPA) where ACPA-positive disease generally
has a worse outcome. Established genetic (e.g., HLA-DRB1
SE alleles) and environmental (e.g., smoking) risk factors
are also predominantly associated with the risk of ACPA-
positive RA [1, 2].
Previous findings on the impact of parity on RA devel-
opment have shown a reduction in RA incidence during
pregnancy [3] and an increased risk post-partum [4]. In
contrast, parity in the long run seems to have no associ-
ation [5–7], or even reduced risk of RA [8]. In a recent
study we reported that parous women of reproductive age
had an increased risk of ACPA-negative RA, and that this
increased risk was seen mainly in women who gave birth
during the year of symptom onset. There was no associ-
ation with risk of ACPA-positive RA [9].
In women with RA, it has been observed that during
pregnancy a majority of patients experience amelioration
[10, 11]. After delivery a relapse of RA is common, espe-
cially in women who breastfeed [12, 13]. There are only a
few studies with diverging results regarding the effect of
parity on the severity of RA (or inflammatory polyarthri-
tis) over time [12–15]. Here, in an unselected population-
based cohort of early RA with extensive information about
lifestyle and environmental factors, in a country with even
access to healthcare, our aim was to explore the impact of
parity on the severity of RA, with stratification for ACPA
status as well as between those in reproductive age and
those who were older at disease onset.
Methods
The EIRA study
We studied female incident RA cases aged 18–70 years,
included between 1996 and 2009 in the Swedish Epidemio-
logical Investigation of Rheumatoid Arthritis (EIRA) study,
a population-based case–control study performed in
parts of Sweden. EIRA has been described more exten-
sively elsewhere [16]. All patients included were diagnosed
by a rheumatologist and fulfilled the American College of
Rheumatology 1987 criteria for RA [17]. The mean duration
from symptom onset was 7 months. All participants
gave informed consent and the study was approved by
the Ethical Review Board at the Karolinska Institute.
Data collection
An extensive questionnaire was used to collect informa-
tion on lifestyle and environmental factors, including par-
ity. Of 2162 identified cases, 2063 (95 %) answered the
questionnaire. In addition, the participating cases provided
blood samples for serological and genetic analyses.
Women were classified as parous (those who had given
birth before or during the year of diagnosis), or nulliparous
at diagnosis. Information about parity history after diagno-
sis was not available. In total, 44 cases lacked information
on parity.
Antibody assays
Immunoscan-RA Mark2 ELISA test (Euro-Diagnostica,
Malmo, Sweden) was used to determine ACPA status [18].
The cut-off was set to 25 U/ml for ACPA-positive RA.
Information about ACPA status was missing in 26 cases.
Clinical outcome
Clinical data were captured from the Swedish Rheuma-
tology Quality Register (SRQ) until 2010. The register
includes information about disease activity and disability
at predefined time points. The process of capturing data
on EIRA patients from SRQ was described previously
[19]. There were 746 patients in EIRA who were not in-
cluded in SRQ at inclusion in EIRA (baseline) or had
missing disease activity parameters at baseline. Some of
the patients had not yet reached the follow-up time points
for data collection in SRQ (see below).
We focused on two outcome measures: the disease
activity score 28 (DAS28) and the health assessment
questionnaire (HAQ). These were evaluated at diagnosis
and at the 3-, 6-, 12- and 24-month follow-up visits in
SRQ. Not all repeated data were complete for DAS28
versus HAQ (0 versus 3 % missing at inclusion, 19 versus
22 % missing at 3 months, 34 versus 36 % missing at
6 months, 10 versus 12 % missing at 12 months and 27
versus 29 % missing at 24 months).
Statistics
We stratified the cases into ACPA-negative/ACPA-positive
disease, and age groups (18–44 and 45–70 years) [9]. We
analyzed the data in three ways: 1) To compare mean
DAS28 and HAQ scores over time in parous and nullipar-
ous women we used mixed models with a first-order
heterogeneous autoregressive correlation structure to allow
for time-dependent variance and declining correlation
between time points further away from each other. 2)
Analysis of covariance was used to analyze differences
in mean DAS28 and HAQ scores at the different time
points between parous and nulliparous women, adjusted
for age at inclusion in EIRA. We further adjusted indi-
vidually for potential confounders (ever/never smoking;
university/no university degree; ever/never use of oral
contraceptives; and area of living). Questions about breast-
feeding were added to the questionnaire in 2006 and a
subanalysis on patients included in years 2006–2009 was
performed with additional adjustment for ever/never
breastfeeding amongst parous women. Adjustments for
the abovementioned factors only marginally altered the
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results and were therefore not retained in the analyses.
3) Logistic regression was performed to obtain odds ratios
with 95 % confidence interval (CI) of having DAS28 or
HAQ above the median at the different time points for
parous women compared to nulliparous women.
All analysis was performed using Statistical Package
for the Social Sciences22 IBM Corporation 1 New




In total, 1237 female cases with concurrent information
on parity and ACPA status in EIRA were also included
in the SRQ. Mean age at inclusion in EIRA was 52 years.
The mean time between first symptoms and RA diagno-
sis was approximately 6 months, and no differences were
found according to ACPA status. In all, 82 % had ever
given birth to a child before diagnosis and 65 % were
ACPA positive (Table 1).
Disease severity over time: mixed models analysis
Over time, parous women aged 18–44 years had on
average higher DAS28 (mean difference 1.17, 95 % CI
0.65 to 1.68) and higher HAQ (mean difference 0.43,
95 % CI 0.20 to 0.66) scores compared to nulliparous
women at each follow-up (Table 2). Among women who
developed ACPA-negative disease at older age, parous
women tended to have a lower DAS28 (Table 2).
No association between parity and severity of ACPA-
positive disease was observed (Table 2).
Parity and severity of ACPA-negative RA at different time
points: analysis of covariance
Since parity only had an impact on the outcome mea-
sures in the ACPA-negative subset, we limited further
analyses to that group and compared mean differences
at each follow-up visit (Table 3).
Parous women in the younger ACPA-negative group
had significantly higher levels of HAQ and DAS28 in all
repeated measurements except at baseline, where there
were no differences. Among those aged >45 years at in-
clusion, parous women had lower levels of DAS28 and
HAQ compared to nulliparous women at all time points,
although the difference only reached statistical significance
at baseline.
High verus low disease severity: logistic regression analysis
Parous women who developed ACPA-negative disease at
reproductive age had higher odds of having a DAS28
and HAQ value above the median compared to nulliparous
women at all follow-up visits, with significance reached at
3, 12 and 24 months for DAS28 and at 12 months for
HAQ. An indication of an opposite effect was seen in
the ACPA-negative older group, especially at baseline
(Table 4).
Discussion
In this study, we demonstrated that parity might have an
impact on disease activity and disability in ACPA-negative
disease. In those who developed RA at reproductive age
(18–44 years), a more severe clinical outcome, measured
with DAS28 and HAQ, was observed among parous as
Table 1 Baseline characteristics of incident rheumatoid arthrits cases included in EIRA
All women
(n = 1237)
ACPA negative ACPA positive
Aged 18–44 (n = 103) Aged 45–70 (n = 331) Aged 18–44 (n = 230) Aged 45–70 (n = 573)
Mean age, years (SD) 51.5 (12.8) 32.9 (7.0) 58.8 (6.6) 34.3 (7.4) 57.6 (7.0)
Parous, n (%) 1009 (81.6) 68 (66.0) 292 (88.2) 135 (58.7) 514 (89.7)
Nulliparous, n (%) 228 (18.4) 35 (34.0) 39 (11.8) 95 (41.3) 59 (10.3)
Mean time between last birth to
symptom onset, years (SD)
24.7 (12.1) 6.8 (4.7) 29.8 (8.1) 7.2 (5.4) 28.8 (9.2)
Mean age at first birth, years (SD) 24 (4.9) 26 (5.3) 24 (4.9) 26 (4.6) 24 (4.8)
Mean number of children (SD) 2.2 (0.9) 1.9 (0.5) 2.4 (0.9) 2.3 (1.2) 2.2 (1.0)
Median DAS28 at inclusion, years (SD) 5.4 (1.2) 5.2 (1.1) 5.6 (1.2) 5.3 (1.1) 5.4 (1.2)
Median HAQ at inclusion (SD) 1.0 (0.6) 1.0 (0.5) 1.1 (0.6) 1.0 (0.6) 1.1 (0.6)
Ever smokers, n (%) 823 (66.7) 59 (57.3) 202 (61.2) 126 (55.0) 436 (76.2)
University degree, n (%) 318 (25.7) 31 (30.1) 85 (25.7) 82 (35.7) 120 (21.0)
Ever use of oral contraceptives before
symptom onset, n (%)
807 (65.6) 89 (89.0) 195 (59.1) 185 (81.1) 338 (59.1)
Received DMARD at inclusion, n (%) 1109 (87) 91 (87) 304 (90) 190 (87) 522 (89)
Received prednisolone at inclusion, n (%) 476 (37) 32 (29) 133 (38) 70 (31) 241 (40)
ACPA Anti-citrullinated protein antibody, DAS28 Disease activity score 28, DMARD Disease-modifying antirheumatic drug, EIRA Epidemiological Investigation of
Rheumatoid Arthritis, HAQ Health assessment questionnaire, SD Standard deviation
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compared to nulliparous women. In the older age group
(45–70 years at inclusion) we observed a milder disease in
parous women, though only statistically significant at
baseline. There was no association between parity and the
severity of ACPA-positive disease, neither among younger
nor among older women.
In a recent study we showed that parous women of
reproductive age (18–44) had a higher risk of ACPA-
negative disease, and we now show that their disease
course also seems to be more severe [10]. Regarding
the effect of parity on RA severity over time, there are
two previous studies with somewhat diverging results
[13, 14]. However, this is the first study investigating
the association between parity and the severity of RA
with stratification for ACPA status.
Strengths of this study include the frequent follow-up
program and the large sample size, which allows us to
perform stratified analyses of different RA subgroups, as
well as different age groups. The inclusion of only incident
cases also ascertains that parity was not affected by the
disease.
Table 2 Adjusted mean differences in clinical outcomes over
the first 2 years between nulliparous and parous women
DAS28 HAQ
Beta (95 % CI), p-value Beta (95 % CI), p-value
All patients 0.11 (−0.05 to 0.27),
p = 0.17
0.06 (−0.00 to 0.13),
p = 0.07
ACPA negative
Aged 18–44 1.17 (0.65 to 1.68),
p < 0.001
0.43 (0.20 to 0.66),
p < 0.001
Aged 45–70 −0.26 (−0.62 to 0.09),
p = 0.14
−0.06 (−0.20 to 0.09),
p = 0.46
ACPA positive
Aged 18–44 0.06 (−0.25 to 0.38),
p = 0.69
0.07 (−0.05 to 0.19),
p = 0.27
Aged 45–70 0.08 (−0.20 to 0.36),
p = 0.57
0.02 (−0.10 to 0.14),
p = 0.70
Mixed models adjusted for age at inclusion in the Epidemiological
Investigation of Rheumatoid Arthritis (EIRA), with nulliparous women as
reference. ACPA Anti-citrullinated protein antibody, CI confidence interval,
DAS28 Disease activity score 28, HAQ Health assessment questionnaire
Table 3 Analysis of covariance with mean differences of
outcome measures (DAS28, HAQ) between nulliparous and
parous women with incident RA included in the EIRA study, at




18–44 years 45–70 years
Beta (95 % CI), p-value Beta (95 % CI), p-value
DAS28
Baseline 0.02 (−0.58 to 0.62),
p = 0.95
−0.78 (−1.19 to −0.37),
p < 0.001
3 months 1.60 (0.81 to 2.40),
p < 0.001
−0.45 (−0.96 to 0.06),
p = 0.96
6 months 1.30 (0.48 to 2.12),
p = 0.002
−0.27 (−0.82 to 0.28),
p = 0.34
12 months 1.22 (0.59 to 1.85),
P < 0.001
−0.31 (−0.73 to 0.12),
p = 0.16
24 months 0.86 (0.18 to 1.55),
p = 0.014
−0.29 (−0.76 to 0.19),
p = 0.24
HAQ
Baseline 0.06 (−0.23 to 0.34),
p = 0.68
−0.35 (−0.56 to −0.14),
p = 0.001
3 months 0.40 (0.05 to 0.74),
p = 0.026
−0.12 (−0.32 to 0.08),
p = 0.24
6 months 0.44 (0.13 to 0.75),
p = 0.006
−0.09 (−0.30 to 0.12),
p = 0.38
12 months 0.43 (0.16 to 0.69),
p = 0.002
−0.02 (−0.20 to 0.16),
p = 0.80
24 months 0.48 (0.14 to 0.82),
p = 0.006
−0.17 (−0.38 to 0.05),
p = 0.13
Analysis of covariance adjusted for age at inclusion in the Epidemiological
Investigation of Rheumatoid Arthritis (EIRA), with nulliparous women as
reference. ACPA Anti-citrullinated protein antibody, CI confidence interval,
DAS28 Disease activity score 28, HAQ health assessment questionnaire, RA
Rheumatoid arthritis





Aged 18 − 44 Aged 45 − 70
OR (95 % CI), p-value OR (95 % CI), p-value
DAS28
Baseline 1.87 (0.62 to 5.69),
p = 0.27
0.37 (0.18 to 0.80),
p = 0.011
3 months 4.96 (1.37 to 18.1),
p = 0.015
0.51 (0.24 to 1.08),
p = 0.08
6 months 2.66 (0.78 to 9.15),
p = 0.12
0.37 (0.16 to 0.85),
p = 0.018
12 months 4.49 (1.37 to 14.7),
p = 0.013
0.89 (0.44 to 1.77),
p = 0.97
24 months 3.56 (1.07 to 11.9),
p = 0.039
0.67 (0.30 to 1.50),
p = 0.33
HAQ
Baseline 0.58 (0.20 to 1.69),
p = 0.32
0.53 (0.26 to 1.07),
p = 0.08
3 months 3.04 (0.90 to 10.3),
p = 0.07
1.29 (0.62 to 2.67),
p = 0.50
6 months 2.42 (0.71 to 8.23),
p = 0.16
1.01 (0.47 to 2.14),
p = 0.99
12 months 7.92 (2.02 to 31.0),
p = 0.003
1.15 (0.57 to 2.33),
p = 0.69
24 months 2.14 (0.65 to 7.06),
p = 0.21
0.95 (0.42 to 2.17),
p = 0.90
Logistic regression adjusted for age at inclusion in the Epidemiological
Investigation of Rheumatoid Arthritis (EIRA), with the odds ratio (OR) of having
an outcome measure (DAS28 and HAQ) higher than median for a parous
woman. ACPA Anti-citrullinated protein antibody, CI confidence interval, DAS28
Disease activity score 28, HAQ Health assessment questionnaire
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One limitation was the lack of information about par-
ity after diagnosis. If ACPA-negative women had more
pregnancies after disease onset it might have affected
our results on disease severity over time. However, the
number of women who might have become pregnant
within the 2-year follow-up time is probably limited (178
women were in the age group 18–35 years). Another
limitation was the lack of disease severity parameters at
baseline in a subset of patients. In a failure analysis, no
major differences in parity (78 versus 82 % in the pre-
sented population) or university degree (26 versus 26 %)
were found for those included in EIRA only compared
to those included in both EIRA and SRQ.
Hypothetically, our findings may be explained by immu-
nomodulatory changes related to pregnancy, for example
a decrease of anti-inflammatory cytokines [20] and regula-
tory CD4+ T cells [21] postpartum, which could drive the
progression of ACPA-negative RA in younger women,
especially close to delivery. In a study of a population
of North American natives highly predisposed to RA,
the highest incidence of RA was observed in the first
postpartum year [22]. This suggests that reversal of hor-
monal and immunologic changes during pregnancy that
favor immune tolerance (and prevent maternal rejection
of the fetus) may affect RA development and increase
early disease severity.
The impact of parity on disease activity and disability
in ACPA-negative disease among women aged 18–44 years
might be confined to the postpartum period. However,
since there were too few observations to study RA pro-
gression directly after delivery, we included all women
aged 18–44 years in the analysis. Another hypothesis is
that ACPA-negative younger women who had been preg-
nant could have poorer response to treatment or lesser
compliance to prescribed medications than ACPA-negative
women who had not yet been pregnant, certainly if they
are planning new pregnancies. However, we cannot ex-
clude that women who had not been pregnant before
diagnosis also are planning pregnancy in the near future.
Other possible explanations include an impact of sleep
disturbance and other factors that could influence pain in
the postpartum period. This should be further studied.
In older women, the influence of parity may reflect the
influence of related lifestyle factors, or a long-term impact
of hormone-related factors, which have been shown to be
more important for seronegative RA [23].
Conclusion
Parity may be a predictor of higher DAS28 and HAQ
compared to nulliparity in ACPA-negative RA women of
reproductive age at diagnosis, but seemed to be a predictor
of less severe disease amongst older women, at least at
baseline. Parity did not seem to be a predictor of sever-
ity in ACPA-positive disease. These findings indicate that
immunomodulatory changes during and after pregnancy
may have specific impact on the ACPA-negative RA
phenotype. Further studies of the underlying mechanisms
may be the basis for a particular management of ACPA-
negative younger women with RA in the future.
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